Critical Illness, Thrombosis
Conditions
Brief summary
Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.
Interventions
DIAGNOSTIC_TESTSerum anti-Xa activity
4 hours after third dose of dalteparin, serum anti-Xa activity is measured
Sponsors
Medical University of Gdansk
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Circulatory failure * Supported by continuous infusion of noradrenaline or noradrenaline and argipressin * Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.
Exclusion criteria
* Contraindications for dalteparin * Severe coagulopathy * Acute or subacute bacterial endocarditis * Pregnant women * BMI (body mass index) \> 30kg/m2 * Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2 * Renal replacement therapy * The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-Xa activity | 4 hours after third dose | IU anty-Xa/ml |
Countries
Poland
Contacts
Primary ContactJan Stefaniak, MD.
Outcome results
None listed